Lower New TB Drug Price Further- MSF

DOCTORS Without Borders (MSF) says they acknowledge the lower price offered to the government of South Africa for newer anti tuberculosis (TB) drug, delamanid, but have called for it to be significantly lower and expanded to all countries in need.

By Michael Gwarisa

Mylan, which licenses the drug from the patent-holder Otsuka, will charge about US$940 for a six-month treatment course about $157 per month as of 1 June 2020 in South Africa. Delamanid is used in combination with other drugs to treat people with drug-resistant TB (DR-TB), including the hard to treat extensively drug-resistant TB (XDR-TB)

Delamanid is one of the most expensive drugs used to treat drug-resistant tuberculosis (DR-TB), priced at approximately R 25 000 ($1,700)** for a six-month treatment course R4 000 ($283 a month) through the Global Drug Facility, a TB drug and diagnostic procurement mechanism operating out of a UN agency.

It is just one of multiple drugs needed to treat the disease. Its high price is a key driver of the high overall cost of treating people with multidrug-resistant TB (MDR-TB) and XDR-TB. A full 20-month treatment course for one person can cost nearly R120 000 ($8,000) to R180 000 ($12,000) through GDF, depending upon the length of treatment and the other drugs that make up the treatment regimen.

The high price has had a chilling effect on treatment scale-up: although delamanid was conditionally approved by the European Medicines Agency in April 2014, as of the end of August 2019, only 2,902 people have ever been treated with delamanid according to the DR-TB Scale-Up Treatment Action Team of global TB experts, which receives updates from National TB Programmes and large treatment providers, such as MSF.

The World Health Organization’s (WHO) treatment guidelines prioritise the use of newer drugs as part of all-oral regimens for the treatment of MDR-TB and XDR-TB. MSF urges more countries to make the switch from older, toxic treatments that need to be injected to all-oral regimens that contain the newer drugs, including delamanid. These newer drugs are critical to improving the otherwise abysmal cure rates of 55% and 34% for MDR-TB and XDR-TB, respectively.

Use of the newer TB drugs is also urgently needed for children with MDR-TB in order to improve treatment outcomes and reduce the risks of side effects.

However, the R 14 000 ($940) price for delamanid offered by Mylan to South Africa remains too high. It is also not clear whether Mylan plans to offer this price to all countries.

Countries facing high rates of resistance specially to fluoroquinolone*** drugs, like India, should take effective measures including overriding patents through compulsory licenses so that generic manufacturers can enter the supply chain and bring the price down further. Researchers from the University of Liverpool have calculated that delamanid could be produced and sold at a profit for much less – ranging from R74 – R237 ($5-16) per month if the drug is scaled up by national TB programmes.

Dr Stobdan Kalon, MSF Medical Advisor, India 

“We constantly struggle to successfully treat people with XDR-TB that have fluoroquinolone resistance and children with MDR-TB at our Mumbai clinic, which is a grave concern given the unacceptably high rates of treatment failure and death. In order to improve the chance for a cure, these patients need effective treatment regimens and immediate access to newer drugs, bedaquiline and delamanid.

Even at nearly R14 000 ($940), delamanid remains one of the most expensive DR-TB drugs, and its high price will continue to have a chilling effect on the scale-up of this drug in national TB programmes. As long as these new drugs are priced out of reach for TB programmes, an all-oral treatment regimen for people everywhere with pre-XDR and XDR and children with MDR-TB will remain a distant reality and people will continue to suffer the devastating side effects of older drugs that have to be injected, including permanent deafness.

Otsuka and Mylan must further drop the price of delamanid to ensure that TB programmes are able to afford and scale-up the use of all-oral treatment regimens



Related posts